Fig. 4.

(A and B) Changes in MAP (A) and HR (B) after intra-RVLM microinjections of Abn CBD (0.4 μg) or an equal volume of vehicle in conscious male Sprague-Dawley rats pretreated (30 minutes earlier) with NPLA (selective nNOS inhibitor; 250 pmol). Pretreatment with NPLA virtually abolished the GPR18 (Abn CBD)-mediated hypotensive response, which suggests nNOS involvement in GPR18 signaling. (C and D) AUC data generated from the time course values over the pretreatment (0–30 minutes) and treatment (30–60 minutes) periods. The left two bars in the AUC graph show pretreatment. All pretreatment data from groups of rats that received the same drugs were combined for clarity. Six rats per group were used except for the saline plus vehicle or Abn CBD groups (n = 3 each). *P < 0.05 versus control (vehicle); ^#P < 0.05 versus Abn CBD. AbC, Abn CBD; AUC, area under the curve; ΔHR, change in HR; ΔMAP, change in MAP; Sal, saline; Veh, vehicle (methyl acetate).